StemCell InstituteStemCell Institute Inc.7096東証グロース医薬品FY ending Mar 2026, consolidated, J-GAAP
StemCell Institute brought in ¥2.81B in revenue.
Out of every ¥100 of sales, about ¥7 is left as operating profit.
Revenue changed +4.9% from the prior year, operating profit -51.6%.
FY ending Mar 2025 → FY ending Mar 2026
FY ending Mar 2025 → FY ending Mar 2026
For every ¥100 StemCell Institute sells, how much goes where, and how much is kept.
Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.
EDINET (FSA Japan)
有価証券報告書-第27期(2025/04/01-2026/03/31)
EDINET (FSA Japan)
有価証券報告書-第26期(2024/04/01-2025/03/31)
EDINET (FSA Japan)
有価証券報告書-第25期(2023/04/01-2024/03/31)
EDINET (FSA Japan)
有価証券報告書-第24期(2022/04/01-2023/03/31)
EDINET (FSA Japan)
有価証券報告書-第23期(令和3年4月1日-令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書-第22期(令和2年4月1日-令和3年3月31日)
Extracted from XBRL: 49 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.